AbbVie (ABBV) ended the recent trading session at $201.64, demonstrating a -1.73% swing from the preceding day's closing price. This change was narrower than the S&P 500's daily loss of 4.84%. On the ...

AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in ...

In a regulatory filing, AbbVie (ABBV) disclosed that reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on AbbVie (ABBV – Research Report), with a price target ...

We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

AbbVie (ABBV) rebounds after losses, gaining ~% as analysts stay bullish. Discover why its obesity drug deal boosts long-term ...

Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.2%, CME Group (Symbol: CME) is down about 0.5%, and Cisco Systems Inc (Symbol ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have ...